Soligenix (NASDAQ:SNGX) posted its earnings results on Tuesday. The biopharmaceutical company reported ($0.12) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.14) by $0.02, Fidelity Earnings reports. Soligenix had a negative net margin of 157.34% and a negative return on equity of 140.01%. The firm had revenue of $1.50 million during the quarter, compared to the consensus estimate of $1.40 million.
NASDAQ:SNGX traded down $0.07 during mid-day trading on Wednesday, hitting $1.05. 1,300 shares of the company’s stock traded hands, compared to its average volume of 154,950. Soligenix has a 1 year low of $0.65 and a 1 year high of $2.20. The stock has a market capitalization of $21.35 million, a P/E ratio of -1.60 and a beta of 1.16. The business has a 50 day simple moving average of $1.02. The company has a current ratio of 2.20, a quick ratio of 2.20 and a debt-to-equity ratio of 0.02.
Several equities analysts have weighed in on the stock. Maxim Group restated a “buy” rating and set a $4.00 target price on shares of Soligenix in a report on Thursday, May 16th. ValuEngine upgraded shares of Soligenix from a “sell” rating to a “hold” rating in a report on Thursday, July 18th.
Soligenix, Inc, a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, BioTherapeutics and Vaccines/BioDefense. The BioTherapeutics segment develops SGX301, a photodynamic therapy, which is in Phase III clinical trial to treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that has completed Phase II clinical trial to treat oral mucositis in head and neck cancer.
Further Reading: Hedge Funds Explained
Receive News & Ratings for Soligenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soligenix and related companies with MarketBeat.com's FREE daily email newsletter.